Andrew P Ambrosy

Dr. Andrew P Ambrosy


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2022 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
DTDiana L. Tobler
Diana L. Tobler
APAlix J. Pruzansky
Alix J. Pruzansky
SNSahar Naderi
Sahar Naderi
AAAndrew P Ambrosy
Andrew P Ambrosy
JSJustin J. Slade
Justin J. Slade

4 July 2022 in JACC
Verified
Journal Article
Closed access
AAAndrew P Ambrosy
Andrew P Ambrosy
RPRishi V. Parikh
Rishi V. Parikh
SSSue Hee Sung
Sue Hee Sung
TTThida C. Tan
Thida C. Tan
ANAnand Narayanan
Anand Narayanan
AGAlan S. Go
Alan S. Go

22 November 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AAAndrew P Ambrosy
Andrew P Ambrosy
RPRishi V. Parikh
Rishi V. Parikh
SSSue Hee Sung
Sue Hee Sung
ANAnand Narayanan
Anand Narayanan
RMRajeev Masson
Rajeev Masson
AGAlan S. Go
Alan S. Go
Heart failure (HF) is a global public health problem that affects an estimated 64 million people worldwide.1-3 In the US alone, more than 6 million patients have been diagnosed with HF and in excess of 1 million annual hospital admissions have had HF as a primary discharge diagnosis.4 Despite the increasing burden of hospitalizations for worsening HF (WHF), our understanding of epidemiological factors, patient clinical characteristics, care management, and outcomes in patients admitted for WHF is based almost entirely on observational studies relying on administrative or claims data and/or national reporting databases or quality improvement registries.4 However, these data sources are intrinsically limited by the accuracy and completeness of diagnostic coding and/or voluntary reporting. Furthermore, signs and symptoms of HF inherently lack sensitivity and specificity, and overlap occurs with other common cardiovascular and noncardiovascular conditions, raising the possibility of misclassification.5

15 August 2022 in Medical Care
Verified
Journal Article
Open access
AGAlan S. Go
Alan S. Go
TTThida C. Tan
Thida C. Tan
KHKate M. Horiuchi
Kate M. Horiuchi
DLDenise Laws
Denise Laws
AAAndrew P Ambrosy
Andrew P Ambrosy
FIfor the KP NOURISH Study Investigators
for the KP NOURISH Study Investigators
Background: Inability to adhere to nutritional recommendations is common and linked to worse outcomes in patients with nutrition-sensitive conditions. Objectives: The purpose of this study is to evaluate whether medically tailored meals (MTMs) improve outcomes in recently discharged adults with nutrition-sensitive conditions compared with usual care. Research Design: Remote pragmatic randomized trial. Subjects: Adults with heart failure, diabetes, or chronic kidney disease being discharged home between April 27, 2020, and June 9, 2021, from 5 hospitals within an integrated health care delivery system. Measures: Participants were prerandomized to 10 weeks of MTMs (with or without virtual nutritional counseling) compared with usual care. The primary outcome was all-cause hospitalization within 90 days after discharge. Exploratory outcomes included all-cause and cause-specific health care utilization and all-cause death within 90 days after discharge. Results: A total of 1977 participants (MTMs: n=993, with 497 assigned to also receive virtual nutritional counseling; usual care: n=984) were enrolled. Compared with usual care, MTMs did not reduce all-cause hospitalization at 90 days after discharge [adjusted hazard ratio, aHR: 1.02, 95% confidence interval (CI), 0.86–1.21]. In exploratory analyses, MTMs were associated with lower mortality (aHR: 0.65, 95% CI, 0.43–0.98) and fewer hospitalizations for heart failure (aHR: 0.53, 95% CI, 0.33–0.88), but not for any emergency department visits (aHR: 0.95, 95% CI, 0.78–1.15) or diabetes-related hospitalizations (aHR: 0.75, 95% CI, 0.31–1.82). No additional benefit was observed with virtual nutritional counseling. Conclusions: Provision of MTMs after discharge did not reduce risk of all-cause hospitalization in adults with nutrition-sensitive conditions. Additional large-scale randomized controlled trials are needed to definitively determine the impact of MTMs on survival and cause-specific health care utilization in at-risk individuals.

1 September 2020 in JACC
Verified
Journal Article
Closed access
AAAndrew P Ambrosy
Andrew P Ambrosy
EBEugene Braunwald
Eugene Braunwald
DMDavid A. Morrow
David A. Morrow
ADAdam D. DeVore
Adam D. DeVore
KMKevin McCague
Kevin McCague
EVEric J. Velazquez
Eric J. Velazquez

1 May 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
RMRJ Mentz
RJ Mentz
AAAndrew P Ambrosy
Andrew P Ambrosy
JEJustin Ezekowitz
Justin Ezekowitz
GLGregory D. Lewis
Gregory D. Lewis
JBJaved Butler
Javed Butler
OIon behalf of the HEART-FID Trial Investigators
on behalf of the HEART-FID Trial Investigators
Background: Iron deficiency (ID) has a prevalence of ≈40% to 50% among patients in heart failure (HF) with reduced ejection fraction and is associated with worse prognosis. Several trials demonstrated that intravenous ferric carboxymaltose leads to early and sustained improvement in patient-reported outcomes and functional capacity in patients with HF with reduced ejection fraction with ID, yet morbidity and mortality data are limited. Methods: The objective of the HEART-FID trial (Ferric Carboxymaltose in Heart Failure With Iron Deficiency) is to assess efficacy and safety of ferric carboxymaltose compared with placebo as treatment for symptomatic HF with reduced ejection fraction with ID. HEART-FID is a multicenter, randomized, double-blind, placebo-controlled trial enrolling ≈3014 patients at ≈300 international centers. Eligible patients are aged ≥18 years in stable chronic HF with New York Heart Association functional class II to IV symptoms, ejection fraction ≤40%, ID (ferritin <100 ng/mL or ferritin 100–300 ng/mL with a transferrin saturation <20%), and documented HF hospitalization or elevated N-terminal pro-brain natriuretic peptide. Consented patients are assigned to ferric carboxymaltose or placebo at baseline, with repeated visits/assessments every 6 months for additional study drug based on hemoglobin and iron indices for the trial duration. The primary end point is a hierarchical composite of death and HF hospitalization at 12 months and change from baseline to 6 months in the 6-minute walk test distance. Conclusions: The HEART-FID trial will inform clinical practice by clarifying the role of long-term treatment with intravenous ferric carboxymaltose, added to usual care, in ambulatory patients with symptomatic HF with reduced ejection fraction with ID. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03037931.